Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $208.00. The company’s shares closed last Friday at $285.51.
According to TipRanks, Syed is an analyst with an average return of -16.6% and a 35.04% success rate. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Biogen, and Coherus Biosciences.
The word on The Street in general, suggests a Hold analyst consensus rating for Amgen with a $259.57 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.65 billion and a net profit of $2.14 billion. In comparison, last year the company earned a revenue of $6.71 billion and had a net profit of $1.88 billion
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
- Amgen presents new Phase 1 AMG 133 data at WCIRDC 2022
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi
